Susquehanna International Group
CLDX icon

Susquehanna International Group’s Celldex Therapeutics CLDX Stock Holding History

Susquehanna International Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.14M Buy
+35,948
New +$980K ﹤0.01% 7542
2025
Q4 		– Sell
-27,367
Closed -$721K – 12474
2025
Q3 		$708K Sell
27,367
-84,032
-75% -$1.95M ﹤0.01% 8166
2025
Q2 		$2.27M Buy
111,399
+17,729
+19% +$345K ﹤0.01% 5528
2025
Q1 		$1.7M Buy
93,670
+27,636
+42% +$617K ﹤0.01% 5907
2024
Q4 		$1.67M Buy
66,034
+1,458
+2% +$39.6K ﹤0.01% 5710
2024
Q3 		$2.19M Buy
64,576
+16,759
+35% +$639K ﹤0.01% 5086
2024
Q2 		$1.77M Sell
47,817
-23,401
-33% -$883K ﹤0.01% 5330
2024
Q1 		$2.99M Buy
71,218
+22,330
+46% +$917K ﹤0.01% 4525
2023
Q4 		$1.94M Sell
48,888
-8,572
-15% -$252K ﹤0.01% 5425
2023
Q3 		$1.58M Buy
57,460
+44,576
+346% +$1.4M ﹤0.01% 5615
2023
Q2 		$437K Sell
12,884
-48,522
-79% -$1.64M ﹤0.01% 8617
2023
Q1 		$2.21M Buy
61,406
+8,246
+16% +$356K ﹤0.01% 4927
2022
Q4 		$2.37M Sell
53,160
-88,391
-62% -$3.16M ﹤0.01% 4410
2022
Q3 		$3.98M Buy
141,551
+119,586
+544% +$3.67M ﹤0.01% 3524
2022
Q2 		$592K Sell
21,965
-80,737
-79% -$2.34M ﹤0.01% 7847
2022
Q1 		$3.5M Buy
102,702
+18,213
+22% +$582K ﹤0.01% 4326
2021
Q4 		$3.27M Sell
84,489
-69,471
-45% -$3.03M ﹤0.01% 4499
2021
Q3 		$8.31M Buy
153,960
+47,512
+45% +$2.23M ﹤0.01% 3144
2021
Q2 		$3.56M Sell
106,448
-524,561
-83% -$14.4M ﹤0.01% 4687
2021
Q1 		$13M Buy
631,009
+319,272
+102% +$7.33M ﹤0.01% 2391
2020
Q4 		$5.46M Buy
+311,737
New +$5.61M ﹤0.01% 3285
2020
Q3 		– Sell
-13,863
Closed -$162K – 10582
2020
Q2 		$180K Sell
13,863
-19,298
-58% -$85.5K ﹤0.01% 9128
2020
Q1 		$55K Sell
33,161
-28,548
-46% -$64.5K ﹤0.01% 9641
2019
Q4 		$138K Buy
61,709
+21,256
+53% +$49.3K ﹤0.01% 8988
2019
Q3 		$86K Buy
+40,453
New +$93.6K ﹤0.01% 9619
2019
Q2 		– Sell
-23,882
Closed -$81.1K – 10256
2019
Q1 		$117K Buy
23,882
+15,802
+196% +$83.1K ﹤0.01% 8180
2018
Q4 		$24K Buy
+8,080
New +$39.7K ﹤0.01% 8648
2018
Q2 		– Sell
-9,376
Closed -$328K – 9662
2018
Q1 		$328K Sell
9,376
-9,329
-50% -$361K ﹤0.01% 7468
2017
Q4 		$796K Sell
18,705
-1,038
-5% -$44.5K ﹤0.01% 5702
2017
Q3 		$847K Buy
19,743
+13,591
+221% +$509K ﹤0.01% 5572
2017
Q2 		$228K Buy
6,152
+3,469
+129% +$153K ﹤0.01% 8062
2017
Q1 		$146K Sell
2,683
-11,988
-82% -$624K ﹤0.01% 8212
2016
Q4 		$779K Buy
+14,671
New +$835K ﹤0.01% 6044
2016
Q3 		– Sell
-2,943
Closed -$183K – 8436
2016
Q2 		$194K Sell
2,943
-16,754
-85% -$1.06M ﹤0.01% 7638
2016
Q1 		$1.12M Sell
19,697
-36,640
-65% -$4.12M ﹤0.01% 4867
2015
Q4 		$13.3M Sell
56,337
-3,087
-5% -$673K 0.01% 1505
2015
Q3 		$9.39M Buy
59,424
+27,031
+83% +$7.65M ﹤0.01% 1901
2015
Q2 		$12.3M Buy
32,393
+13,034
+67% +$5.18M 0.01% 1773
2015
Q1 		$8.09M Sell
19,359
-25,714
-57% -$9.2M ﹤0.01% 2107
2014
Q4 		$12.3M Sell
45,073
-14,689
-25% -$3.65M ﹤0.01% 1794
2014
Q3 		$11.6M Buy
59,762
+17,795
+42% +$3.88M ﹤0.01% 1952
2014
Q2 		$10.3M Buy
41,967
+17,277
+70% +$3.9M ﹤0.01% 2091
2014
Q1 		$6.54M Buy
24,690
+6,872
+39% +$2.63M ﹤0.01% 2530
2013
Q4 		$6.47M Sell
17,818
-1,672
-9% -$644K ﹤0.01% 2580
2013
Q3 		$10.4M Buy
19,490
+5,174
+36% +$1.77M 0.01% 1865
2013
Q2 		$3.35M Buy
+14,316
New +$2.82M ﹤0.01% 3139

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Susquehanna International Group's CLDX Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 35,948 shares worth $1.14M. The stake represents ﹤0.01% of the portfolio and ranks #7542 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in CLDX as recently as Q3 2025.

Susquehanna International Group first reported a position in CLDX in Q2 2013 and has held it in 46 quarters since. The position peaked at $13.3M in Q4 2015. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Susquehanna International Group held 35,948 shares of Celldex Therapeutics worth $1.14M as of Q1 2026.
  • Celldex Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7542 holding.
  • Susquehanna International Group first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 46 quarters since.
  • Susquehanna International Group's Celldex Therapeutics position peaked at $13.3M in Q4 2015.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.